8 results about "Vitronectin" patented technology

Pharmaceutical compositions including one or more integrin activators capable of capable of improving the anti-cancer activity of nature t-cells, wherein the integrin activators target integrins including, but not limited to, α4β1, α4β7, α5β1, αLβ2 and / or αVβ3 improving binding to their respective ligands including, but not limited to, VCAM-1, fibronectin, MAdCAM-1, ICAM-1, ICAM-2, and / or vitronectin, wherein the compositions treat, ameliorate, and / or reduce symptoms of diseases, maladies, and cancers, and methods for making and using for preventing, treating, ameliorating, and / or reducing symptoms of cancerous tumors, cancerous solid tumors, other cancerous growth, and / or other cancerous.

The invention relates to a cell attachment peptide containing an RGD amino acid motif, characterized by a material-side motif derived from poly-L-lysine and a cell-side motif derived from vitronectin. The peptide may be used to functionalize materials for use in cell cultures, such as microcarriers, scaffolds, and substrates.

The application belongs to the technical field of medical detection, and discloses a biomarker for diagnosing hepatocellular carcinoma and application thereof. The biomarker comprises a combination of coding nucleic acids of alpha-1-microglobulin, vitronectin, apolipoprotein A1, fibrinogen gamma chain, fibrinogen alpha chain and albumin; and the coding nucleic acids comprise mRNA or cDNA. The application purifies CD147 positive extracellular vesicles from plasma, and performs PCR detection on mRNA of hepatocellular carcinoma biomarkers carried in the extracellular vesicles. A HCC Score diagnosis model is constructed based on detection results of the biomarkers, and has high diagnostic sensitivity and specificity for hepatocellular carcinoma, has great potential in screening of early hepatocellular carcinoma, and has important practical significance for early diagnosis of hepatocellular carcinoma.

To provide an improved method for treating IdiopathicPulmonaryFibrosis (IPF).SOLUTION: The invention features a polypeptide comprising a variant of plasminogen-activator inhibitor-1 (PAI-1) having a reduced capacity to bind vitronectin, a reduced capacity to interact with the PAI-1 clearance receptor LDL-receptor-related-protein 1 (LRP1), and a capacity to efficiently inhibit neutrophil elastases in presence of neutrophil extracellular traps (NETs). In some embodiments, a polypeptide of the present invention comprises a PAI-1 variant optionally fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions characterized by aberrant neutrophil elastase activity (as an example, idiopathic pulmonary fibrosis).SELECTED DRAWING: Figure 1

The invention belongs to the technical field of Muse cell culture, and discloses a Muse cell culture medium and a culture method of umbilical cord-derived Muse cells. According to the invention, a fibronectin and vitronectin composite matrix and an amplification culture medium A are used for adherent amplification of Muse cells, and the composite matrix can promote specific adhesion, spreading and proliferation of Muse cells. The maintenance medium B is used for recovering the Muse cell dryness, low-viscosity sodium alginate is used in the maintenance medium B to replace traditional methyl cellulose, the culture medium can remarkably improve the cell activity, and meanwhile the Muse cell dryness maintenance and recovery effect is better than that of a traditional MC culture medium. The amplification culture medium A and the maintenance culture medium B provided by the invention can be matched with a programmed amplification-maintenance circulating culture process, the SSEA-3 positive rate and the multidirectional differentiation potential of the cells are stably maintained for a long time while efficient amplification is performed, and the culture medium has a wide application prospect in large-scale Muse cell culture.

Provided is a technology allowing for stable supply of brain microvascular endothelium-like cells. This coating agent for inducing differentiation of pluripotent stem cells into brain microvascular endothelium-like cells contains at least one component of a Laminin-221 fragment or an N-terminal Vitronectin.

A method for functionalizing a hollow fiber membrane for cell expansion, differentiation, harvesting, activation, or any combination thereof of target cells (e.g., natural killer cells) includes contacting a biotinylated molecule to a surface of the hollow fiber membrane including an extracellular matrix component, the biotinylated molecule binding to the extracellular matrix component and having an affinity for the target cells. The biotinylated molecule is selected from the group consisting of: cytokine, epitope, ligand, monoclonal antibody, stains, aptamer, and combinations thereof. The extracellular matrix component selected from the group consisting of: fibronectin, vitronectin, fibrinogen, collagen, laminin, streptavidin, truncations thereof, and combinations thereof.

To provide a method for producing retinal pigment epithelial cells.SOLUTION: A method of producing retinal pigment epithelium (RPE) cells, comprising the steps of: (a) culturing a cell population of undifferentiated human pluripotent stem cells on an adherent surface selected from the group consisting of laminin, fibronectin, vitronectin, collagen I and collagen IV in a medium comprising nicotinamide as a differentiation-inducing agent and lacking activin A under feeder cell-free conditions to obtain differentiated cells; (b) culturing the differentiated cells on the adherent surface in a medium comprising nicotinamide and one or more members of the TGF β superfamily selected from the group consisting of TGF β 1, TGF β 3, and activin A to obtain RPE cells, wherein at least 50% of the cells in the population of cells are Oct4 + TRA-1-60 +.SELECTED DRAWING: Figure 1